Cytek Biosciences Inc (CTKB) — Capital Reinvestment Ratio
Latest as of June 2025:
14.60x
Cytek Biosciences Inc (CTKB) has a Capital Reinvestment Ratio of 14.60x as of June 2025, meaning it reinvests 15% of its operating cash flow ($108.00K) in capital expenditures ($1.58 Million). See CTKB free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
14.60x
Capex / Operating Cash Flow
Operating Cash Flow
$108.00K
USD
Capital Expenditures
$1.58 Million
USD
Data as of
Jun 2025
Most recent filing
Cytek Biosciences Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks Cytek Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Cytek Biosciences Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for Cytek Biosciences Inc from 2020 to 2024. For live market cap and broader valuation context, see Cytek Biosciences Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | $25.38 Million | $3.52 Million | ▼ -84.8% |
| 2023 | 0.91x | $5.28 Million | $4.83 Million | ▼ -3.0% |
| 2021 | 0.94x | $4.63 Million | $4.36 Million | ▲ +823.4% |
| 2020 | 0.10x | $15.16 Million | $1.55 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow